Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

7.05USD
21 Sep 2018
Change (% chg)

$-0.41 (-5.50%)
Prev Close
$7.46
Open
$7.45
Day's High
$7.54
Day's Low
$7.01
Volume
112,151
Avg. Vol
68,517
52-wk High
$13.05
52-wk Low
$4.78

Select another date:

Thu, May 24 2018

Photo

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

Select another date: